Along with continuing efforts to find a cure for COVID-19, most pharmaceutical companies have been continuing their R&D projects and clinical trials for the treatment of other critical diseases. The global pharmaceuticals market is expected to grow at a 7% CAGR over the next seven years to reach $2.15 trillion by 2027.
AbbVie Inc . (NYSE:ABBV), Novo Nordisk A/S (NVO), and Bristol-Myers Squibb Company (NYSE:BMY) have recently hit their 52-week stock price highs thanks to their impressive R&D projects and viable drug portfolios. As such, we think these stocks are solid additions to one’s portfolio now.